Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) reported Thursday it is accelerating preclinical activities for two of its lead programs as it prepares for upcoming clinical trials.
The longevity-focused biotechnology company is advancing its GF-1002 program toward a European Clinical Trial Authorisation submission. The company has initiated Chemistry, Manufacturing, and Controls work with its partner Exothera to ensure clinical supply production meets Good Manufacturing Practice standards. Pivotal efficacy studies are currently underway with CRO partners Physiogenex and Accelera, evaluating GF-1002 in both early and advanced stages of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
For its GF-1004 program, Genflow has submitted a protocol amendment to its ongoing proof-of-concept clinical trial in aged dogs. The amendment specifies intravenous dose rates to ensure consistent delivery and enhance patient safety. This randomized, controlled trial, which began in March in collaboration with Syngene, aims to evaluate the safety and efficacy of the company’s SIRT6-centenarian gene therapy in addressing age-related decline in dogs.
"This update reflects the growing maturity of our pipeline and our continued commitment to advancing science-backed therapies in healthy aging," said Dr. Eric Leire, CEO of Genflow, in the press release.
Genflow Biosciences, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is developing gene therapies focused on decelerating the aging process. The company’s lead compound, GF-1002, delivers a centenarian variant of the SIRT6 gene, which has shown promising results in preclinical studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.